Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozein proline in IgA nephropathy
ChiCTR2400079954Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of henagliflozin in IgA nephropathy (IgAN) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: 24 hour urine protein at 12 months and Urinary protein-to-creatinine ratio (UPCR). Planned start Jan 2024; status: not yet recruiting.
02
Drugs
henagliflozin
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR2400079954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079954.